X
Search
X

Patient Support Helpline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Us TOO Presents: Prostate Cancer Pathways

Prostate Cancer Pathways Event and Webcast
Presented by Us TOO
Recorded Saturday, November 9, 2019
at Northwestern Medicine, Robert H. Lurie Medical Research Center
Chicago, IL

With Presenting Experts:

  • Sean Sachdev, MD – Radiation Treatment Options & Potential/ Probable Side Effects
  • Maha Hussain, MD – Advanced Prostate Cancer & Clinical Trials
  • Nelson Bennett, Jr., MD – Moderator & Sexual Health After Prostate Cancer Treatment
  • Carmen Williams, MS, CGC – Genetics & Genomics
  • Shilajit D. Kundu, MD – Initial Diagnosis: Active Surveillance, Surgical Options, Potential/Probable Side Effects from Surgery
  • Alicia Morgans, MD, MPH – Moderator
  • David J. VanderWeele, MD, PhD – Molecular Testing & Bone Support

CLICK TIME FOR DIRECT LINK TO EACH SEGMENT BELOW

  • 0:10 Intro – Chuck Strand, CEO of Us TOO
  • 2:06 About Us TOO
  • 4:53 Agenda
  • 5:53 Intro to Session 1 Moderator Dr. Nelson Bennett
  • 8:04 Dr. Nelson Bennett
  • 8:20 Intro to Dr. Shilajit Kundu
  • 9:04 Initial Diagnosis: Active Surveillance, Surgical Options & Side Effects
  • 9:41 Scope of Problem
  • 10:27 Incidence
  • 12:41 Risk
  • 13:19 Survival
  • 14:00 PLCO Study of Screening
  • 15:30 USPSTF
  • 16:02 Chance of Localized Prostate Cancer
  • 17:00 Risk of Dying of Prostate Cancer – Surgery v. Watchful Waiting
  • 18:29 PROTECT Trial
  • 19:13 USPSTF Change
  • 19:54 Low Grade Prostate Cancer
  • 20:46 Active Surveillance
  • 23:46 Radical Prostatectomy
  • 24:24 Surgery
  • 26:10 Quality of Life After Prostatectomy – Erectile Function
  • 27:14 Urinary Function
  • 27:36 Bowel Symptoms
  • 28:23 Conclusions
  • 29:55 Intro to Dr. Sean Sachdev
  • 30:43 Radiotherapy
  • 32:30 History
  • 34:46 Evolution of Treatment
  • 36:10 Computerized MLCs (Beam Shaping)
  • 37:18 Intensity Modulated Radiation Treatment
  • 38:45 Arc IMRT – Volumetric Mediated Arc Treatment
  • 40:47 Genitourinary Radiotherapy, Workflow
  • 42:51 Stereotactic Radiotherapy, High Dose Ablative RT
  • 44:05 GammaKnife
  • 45:09 Computer Controlled, Frame-Free Approach
  • 45:57 Applications
  • 47:18 Updates
  • 47:37 NCCN Risk Classification
  • 48:08 Low Risk Treatment
  • 49:15 Dose Escalation RTOG 0126
  • 50:57 Androgen Deprivation Therapy & RT
  • 55:22 Post-Operative Treatment, Radiotherapy
  • 55:40 Adjuvant v. Salvage
  • 56:07 Adjuvant RT Utilization
  • 56:56 ADT
  • 58:24 Androgen v. Salvage RT
  • 1:00:15 Dr. Nelson Bennet – Prostate Cancer & the Penis
  • 1:00:28 Post-RP Sexual Dysfunctions
  • 1:01:01 ED After Prostatectomy
  • 1:01:50 Anatomy
  • 1:02:07 Nerve-Sparing Surgery
  • 1:03:10 Radiation Therapy & ED
  • 1:05:18 Importance of Sexual Function – Psychological Issues
  • 1:05:48 ED & Depression
  • 1:07:00 Erectile Function Recovery
  • 1:09:54 Other Dysfunctions
  • 1:10:00 Dysorgasmia
  • 1:10:30 Orgasm-Associated Urine Leak
  • 1:10:57 Penile Length Alterations
  • 1:13:55 Peyronie's Disease
  • 1:14:30 Treatments
  • 1:14:52 Pills – Phosphodiesterase Type 5 Inhibitors
  • 1:16:17 Vacuum Devices
  • 1:17:20 Transurethral PGE (Muse)
  • 1:17:50 Intracavernosal Injections
  • 1:18:24 Penile Rehabilitation – Prophylactic Therapy
  • 1:20:10 Surgical Options – Penile Prosthesis
  • 1:22:12 Prosthesis – Advantages & Disadvantages
  • 1:23:16 Intro to Cliff Whall, Us TOO Support Group Leader
  • 1:24:29 Patient Perspective
  • 1:43:30 Panel Discussion & Q&A
  • 2:09:00 Intro to Sponsors
  • 2:15:15 Intro to Session 2 Moderator – Dr. Alicia Morgans
  • 2:17:11 Intro to Carmen Williams
  • 2:18:54 Genetics
  • 2:19:56 Genetic Counselors
  • 2:21:50 Genetics 101
  • 2:22:41 Terminology
  • 2:23:59 How Genes Cause Cancer
  • 2:24:33 Normal Human Genome
  • 2:25:20 Somatic v. Germline
  • 2:27:03 Distribution of Cancer
  • 2:27:33 Genetics 201 – Hereditary Conditions
  • 2:29:37 Genetic Counseling Consultations
  • 2:30:31 When to Suspect Hereditary Prostate Cancer
  • 2:31:45 Genes Associated with Hereditary Prostate Cancer
  • 2:32:24 Possible Results
  • 2:33:54 Considerations for Undergoing Genetic Testing
  • 2:35:09 Family that is BRCA+
  • 2:36:42 Genetic Discrimination
  • 2:38:56 Take Home Points – Hereditary Genetic Testing
  • 2:39:31 Genetics 301 – DNA Testing of Tumors
  • 2:42:25 Goals of Somatic Testing
  • 2:43:37 Results
  • 2:44:44 Take Home Points – Somatic Tumor DNA Testing
  • 2:45:18 Resources
  • 2:46:52 Intro to Dr. Maha Hussain
  • 2:48:53 Prostate Cancer Disease States
  • 2:52:08 Metastatic Prostate Cancer
  • 2:54:42 Hypothalamic-Pituitary-Gonadal Axis
  • 2:55:20 Historical Perspective: Androgens & Prostate Cancer
  • 2:56:27 Metastatic Hormone Sensitive Prostate Cancer
  • 2:57:55 Landmarks of FDA Drug Approvals
  • 3:01:16 Metastatic Castration Resistant Prostate Cancer Treatment Options
  • 3:02:00 mCRPC Research Themes/Emerging Data
  • 3:04:46 CARD Clinical Trial
  • 3:05:28 Imaging-Based Progression-Free Survival, Estimates of Overall Survival & PFS
  • 3:06:59 Precision Medicine
  • 3:07:57 Genomic Landscape of SU2C Metastatic Castration Resistant Prostate Cancer
  • 3:08:51 DNA Damage Response & PARP Inhibitors
  • 3:09:56 PROfound Phase 3 Study of Olaparib v. Enzalutamide
  • 3:13:27 Revisiting Chemohormonal & Combined Androgen Deprivation Strategies
  • 3:14:02 CHAARTED
  • 3:15:05 LATITUDE
  • 3:15:40 ENZAMET
  • 3:16:14 Metastatic Hormone Sensitive PCa
  • 3:16:44 Prostate Cancer General Disease States
  • 3:17:23 Non Metastatic Castration-Resistant Prostate Cancer
  • 3:18:18 Demographic & Disease Characteristics at Baseline
  • 3:18:36 Metastasis-Free Survival
  • 3:19:33 Prostate Cancer Survival Over Time
  • 3:21:03 Conquer Prostate Cancer Through Research & Excellence in Care
  • 3:22:02 Dr. Alicia Morgans – Intro to Dr. David J. VanderWeele
  • 3:23:28 Oncology
  • 3:24:52 Why Consider Genomic/Molecular Testing
  • 3:29:38 Homologous Recombination Pathway
  • 3:33:47 Mismatch Repair Pathway
  • 3:44:10 Bone Strength
  • 3:47:16 Risk for Fractures
  • 3:48:20 How Can You Prevent Fractures
  • 3:50:21 Panel Discussion & Q&A

Thank You to Host: Northwestern Medicine, Robert H. Lurie Medical Research Center and Sponsors: Astellas, Pfizer Oncology, Amgen, Genomic Health, Clovis Oncology, Dendreon, Advanced Accelerator Applications, Foundation Medicine, Sanofi Genzyme, and Timm Medical Technologies Inc.